{
  "kind": "all",
  "value": "all",
  "collectionKey": "slides:all:all:all-document-kinds:all-producers:all-orientations",
  "filters": {
    "documentKinds": [],
    "sourceTypes": [],
    "orientations": []
  },
  "total": 319975,
  "page": 3275,
  "pageSize": 60,
  "pageCount": 5333,
  "rows": [
    {
      "docId": "019de074-10e3-7369-8d20-9de5f90f6dda",
      "docSlug": "f8e62a4b9063df71f3b497c8a958ac67",
      "documentTitle": "Sonos | Results Presentation Deck | 41 slides",
      "authorId": "sonos",
      "authorName": "Sonos",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 40,
      "slideType": "appendix_data",
      "function": "analyze_data",
      "notes": "Note: $ in thousands, unaudited.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-10e3-7369-8d20-9de5f90f6dda/40",
      "deckHref": "/decks/019de074-10e3-7369-8d20-9de5f90f6dda",
      "deckAnchorHref": "/decks/019de074-10e3-7369-8d20-9de5f90f6dda#slide-40",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 41,
          "from": 17,
          "beatId": "ae55677e-1f26-416d-8a24-589e2ab02d33",
          "arcName": "Monroe's Motivated Sequence",
          "arcSlug": "monroes-sequence",
          "beatName": "Action",
          "beatSlug": "monroes-sequence-action",
          "evidence": "The presentation concludes with an outlook for FY23 and a summary of key takeaways",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-10e3-7369-8d20-9de5f90f6dda",
      "docSlug": "f8e62a4b9063df71f3b497c8a958ac67",
      "documentTitle": "Sonos | Results Presentation Deck | 41 slides",
      "authorId": "sonos",
      "authorName": "Sonos",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 41,
      "slideType": "cover",
      "function": "front_matter",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-10e3-7369-8d20-9de5f90f6dda/41",
      "deckHref": "/decks/019de074-10e3-7369-8d20-9de5f90f6dda",
      "deckAnchorHref": "/decks/019de074-10e3-7369-8d20-9de5f90f6dda#slide-41",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 41,
          "from": 17,
          "beatId": "ae55677e-1f26-416d-8a24-589e2ab02d33",
          "arcName": "Monroe's Motivated Sequence",
          "arcSlug": "monroes-sequence",
          "beatName": "Action",
          "beatSlug": "monroes-sequence-action",
          "evidence": "The presentation concludes with an outlook for FY23 and a summary of key takeaways",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-117f-7139-b332-c7921487636f",
      "docSlug": "87c4725a75980837aa20227252fd24a0",
      "documentTitle": "Taboola | Mergers and Acquisitions Presentation Deck | 13 slides",
      "authorId": "taboola",
      "authorName": "Taboola",
      "documentKindSlug": "shareholder-letter",
      "documentKindLabel": "Shareholder letter",
      "sourceTypeSlug": "investment_bank",
      "sourceTypeLabel": "Investment bank",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 1,
      "slideType": "cover",
      "function": "front_matter",
      "notes": null,
      "imagePath": "https://imgproxy.kitesheet.com/K_UkDl6UjsIgs_REwW9CtN4T2HbADN1zYAuioUWWccU/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy84N2M0NzI1YTc1OTgwODM3YWEyMDIyNzI1MmZkMjRhMC9wMDAxLmpwZw",
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-117f-7139-b332-c7921487636f/1",
      "deckHref": "/decks/019de074-117f-7139-b332-c7921487636f",
      "deckAnchorHref": "/decks/019de074-117f-7139-b332-c7921487636f#slide-1",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 4,
          "from": 1,
          "beatId": "1d4bb152-192a-4eaa-bb43-2eeb089955ad",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Setup",
          "beatSlug": "setup",
          "evidence": "Introduction to the partnership",
          "position": 0,
          "confidence": 0.7,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": "https://imgproxy.kitesheet.com/i6E95zhMt6GoQinnEs0oWWFNNZX5cMYGx22ODpgQX-g/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy84N2M0NzI1YTc1OTgwODM3YWEyMDIyNzI1MmZkMjRhMC9wMDAxLnBuZw",
      "thumbSrc": "https://imgproxy.kitesheet.com/v27a-KJUJrq6eA98D-NmmGl9IaQotXN9PKFtGoShySU/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy84N2M0NzI1YTc1OTgwODM3YWEyMDIyNzI1MmZkMjRhMC9wMDAxLmpwZw",
      "thumbSrcAlt": "https://imgproxy.kitesheet.com/HeYPUlvigsO0PqAoca8BH7WVQ7UAz13WWj7mV6NNSnM/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy84N2M0NzI1YTc1OTgwODM3YWEyMDIyNzI1MmZkMjRhMC9wMDAxLnBuZw"
    },
    {
      "docId": "019de074-117f-7139-b332-c7921487636f",
      "docSlug": "87c4725a75980837aa20227252fd24a0",
      "documentTitle": "Taboola | Mergers and Acquisitions Presentation Deck | 13 slides",
      "authorId": "taboola",
      "authorName": "Taboola",
      "documentKindSlug": "shareholder-letter",
      "documentKindLabel": "Shareholder letter",
      "sourceTypeSlug": "investment_bank",
      "sourceTypeLabel": "Investment bank",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 2,
      "slideType": "disclaimer",
      "function": "front_matter",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-117f-7139-b332-c7921487636f/2",
      "deckHref": "/decks/019de074-117f-7139-b332-c7921487636f",
      "deckAnchorHref": "/decks/019de074-117f-7139-b332-c7921487636f#slide-2",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 4,
          "from": 1,
          "beatId": "1d4bb152-192a-4eaa-bb43-2eeb089955ad",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Setup",
          "beatSlug": "setup",
          "evidence": "Introduction to the partnership",
          "position": 0,
          "confidence": 0.7,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-117f-7139-b332-c7921487636f",
      "docSlug": "87c4725a75980837aa20227252fd24a0",
      "documentTitle": "Taboola | Mergers and Acquisitions Presentation Deck | 13 slides",
      "authorId": "taboola",
      "authorName": "Taboola",
      "documentKindSlug": "shareholder-letter",
      "documentKindLabel": "Shareholder letter",
      "sourceTypeSlug": "investment_bank",
      "sourceTypeLabel": "Investment bank",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 3,
      "slideType": "thesis_headline",
      "function": "establish_context",
      "notes": "Confetti background suggests a celebratory tone.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-117f-7139-b332-c7921487636f/3",
      "deckHref": "/decks/019de074-117f-7139-b332-c7921487636f",
      "deckAnchorHref": "/decks/019de074-117f-7139-b332-c7921487636f#slide-3",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 4,
          "from": 1,
          "beatId": "1d4bb152-192a-4eaa-bb43-2eeb089955ad",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Setup",
          "beatSlug": "setup",
          "evidence": "Introduction to the partnership",
          "position": 0,
          "confidence": 0.7,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-117f-7139-b332-c7921487636f",
      "docSlug": "87c4725a75980837aa20227252fd24a0",
      "documentTitle": "Taboola | Mergers and Acquisitions Presentation Deck | 13 slides",
      "authorId": "taboola",
      "authorName": "Taboola",
      "documentKindSlug": "shareholder-letter",
      "documentKindLabel": "Shareholder letter",
      "sourceTypeSlug": "investment_bank",
      "sourceTypeLabel": "Investment bank",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 4,
      "slideType": "cover",
      "function": "front_matter",
      "notes": "The slide features a purple background with the logos of Yahoo and Taboola, and an inverted image of a person laughing.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-117f-7139-b332-c7921487636f/4",
      "deckHref": "/decks/019de074-117f-7139-b332-c7921487636f",
      "deckAnchorHref": "/decks/019de074-117f-7139-b332-c7921487636f#slide-4",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 4,
          "from": 1,
          "beatId": "1d4bb152-192a-4eaa-bb43-2eeb089955ad",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Setup",
          "beatSlug": "setup",
          "evidence": "Introduction to the partnership",
          "position": 0,
          "confidence": 0.7,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-117f-7139-b332-c7921487636f",
      "docSlug": "87c4725a75980837aa20227252fd24a0",
      "documentTitle": "Taboola | Mergers and Acquisitions Presentation Deck | 13 slides",
      "authorId": "taboola",
      "authorName": "Taboola",
      "documentKindSlug": "shareholder-letter",
      "documentKindLabel": "Shareholder letter",
      "sourceTypeSlug": "investment_bank",
      "sourceTypeLabel": "Investment bank",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 5,
      "slideType": "other",
      "function": "establish_context",
      "notes": "The slide uses screenshots of Yahoo's mobile interface with purple boxes highlighting the ad placements.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-117f-7139-b332-c7921487636f/5",
      "deckHref": "/decks/019de074-117f-7139-b332-c7921487636f",
      "deckAnchorHref": "/decks/019de074-117f-7139-b332-c7921487636f#slide-5",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 6,
          "from": 5,
          "beatId": "9b0a1f84-6bdb-4f1e-8ef3-996c854135eb",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Complication",
          "beatSlug": "complication",
          "evidence": "Highlighting the growth opportunity",
          "position": 1,
          "confidence": 0.7,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-117f-7139-b332-c7921487636f",
      "docSlug": "87c4725a75980837aa20227252fd24a0",
      "documentTitle": "Taboola | Mergers and Acquisitions Presentation Deck | 13 slides",
      "authorId": "taboola",
      "authorName": "Taboola",
      "documentKindSlug": "shareholder-letter",
      "documentKindLabel": "Shareholder letter",
      "sourceTypeSlug": "investment_bank",
      "sourceTypeLabel": "Investment bank",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 6,
      "slideType": "thesis_headline",
      "function": "quantify_opportunity",
      "notes": "The slide outlines the value proposition of a specific business partnership.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-117f-7139-b332-c7921487636f/6",
      "deckHref": "/decks/019de074-117f-7139-b332-c7921487636f",
      "deckAnchorHref": "/decks/019de074-117f-7139-b332-c7921487636f#slide-6",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 6,
          "from": 5,
          "beatId": "9b0a1f84-6bdb-4f1e-8ef3-996c854135eb",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Complication",
          "beatSlug": "complication",
          "evidence": "Highlighting the growth opportunity",
          "position": 1,
          "confidence": 0.7,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-117f-7139-b332-c7921487636f",
      "docSlug": "87c4725a75980837aa20227252fd24a0",
      "documentTitle": "Taboola | Mergers and Acquisitions Presentation Deck | 13 slides",
      "authorId": "taboola",
      "authorName": "Taboola",
      "documentKindSlug": "shareholder-letter",
      "documentKindLabel": "Shareholder letter",
      "sourceTypeSlug": "investment_bank",
      "sourceTypeLabel": "Investment bank",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 7,
      "slideType": "before_after",
      "function": "quantify_opportunity",
      "notes": "Uses a before-after comparison to illustrate the scale of the acquisition.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-117f-7139-b332-c7921487636f/7",
      "deckHref": "/decks/019de074-117f-7139-b332-c7921487636f",
      "deckAnchorHref": "/decks/019de074-117f-7139-b332-c7921487636f#slide-7",
      "loopMatches": [
        {
          "to": 8,
          "from": 7,
          "name": "Before After",
          "slug": "21-before-after",
          "bestFor": "Product demos, process improvements, ROI justification",
          "matchId": "b0247558-1c20-434b-be12-e6e22bae52d2",
          "evidence": "Before and after financial comparison",
          "position": 0,
          "objective": "Highlighting the financial transformation",
          "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta",
          "confidence": 0.6,
          "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 8,
          "from": 7,
          "beatId": "547d78cc-02c7-4617-9fdd-be216e5feebc",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Problem (Identify pain)",
          "beatSlug": "problem-agitate-solution-problem-identify-pain",
          "evidence": "Financially transformative deal",
          "position": 2,
          "confidence": 0.7,
          "parentBeatName": "Complication",
          "parentBeatSlug": "complication"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-117f-7139-b332-c7921487636f",
      "docSlug": "87c4725a75980837aa20227252fd24a0",
      "documentTitle": "Taboola | Mergers and Acquisitions Presentation Deck | 13 slides",
      "authorId": "taboola",
      "authorName": "Taboola",
      "documentKindSlug": "shareholder-letter",
      "documentKindLabel": "Shareholder letter",
      "sourceTypeSlug": "investment_bank",
      "sourceTypeLabel": "Investment bank",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 8,
      "slideType": "valuation_table",
      "function": "show_valuation_bridge",
      "notes": "The table highlights accretion in both Revenue/Share and Adjusted EBITDA/Share.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-117f-7139-b332-c7921487636f/8",
      "deckHref": "/decks/019de074-117f-7139-b332-c7921487636f",
      "deckAnchorHref": "/decks/019de074-117f-7139-b332-c7921487636f#slide-8",
      "loopMatches": [
        {
          "to": 8,
          "from": 7,
          "name": "Before After",
          "slug": "21-before-after",
          "bestFor": "Product demos, process improvements, ROI justification",
          "matchId": "b0247558-1c20-434b-be12-e6e22bae52d2",
          "evidence": "Before and after financial comparison",
          "position": 0,
          "objective": "Highlighting the financial transformation",
          "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta",
          "confidence": 0.6,
          "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 8,
          "from": 7,
          "beatId": "547d78cc-02c7-4617-9fdd-be216e5feebc",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Problem (Identify pain)",
          "beatSlug": "problem-agitate-solution-problem-identify-pain",
          "evidence": "Financially transformative deal",
          "position": 2,
          "confidence": 0.7,
          "parentBeatName": "Complication",
          "parentBeatSlug": "complication"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-117f-7139-b332-c7921487636f",
      "docSlug": "87c4725a75980837aa20227252fd24a0",
      "documentTitle": "Taboola | Mergers and Acquisitions Presentation Deck | 13 slides",
      "authorId": "taboola",
      "authorName": "Taboola",
      "documentKindSlug": "shareholder-letter",
      "documentKindLabel": "Shareholder letter",
      "sourceTypeSlug": "investment_bank",
      "sourceTypeLabel": "Investment bank",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 9,
      "slideType": "transition",
      "function": "state_next_steps",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-117f-7139-b332-c7921487636f/9",
      "deckHref": "/decks/019de074-117f-7139-b332-c7921487636f",
      "deckAnchorHref": "/decks/019de074-117f-7139-b332-c7921487636f#slide-9",
      "loopMatches": [
        {
          "to": 10,
          "from": 9,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "f37e2460-5beb-410b-90f8-272521031ee4",
          "evidence": "Implied cost of not selecting Taboola",
          "position": 1,
          "objective": "Why Yahoo! selected Taboola",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.5,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 10,
          "from": 9,
          "beatId": "f2a8eea8-9e40-4068-bb01-617ccd48445f",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Solution (Provide relief)",
          "beatSlug": "problem-agitate-solution-solution-provide-relief",
          "evidence": "Why Yahoo! selected Taboola",
          "position": 3,
          "confidence": 0.7,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-117f-7139-b332-c7921487636f",
      "docSlug": "87c4725a75980837aa20227252fd24a0",
      "documentTitle": "Taboola | Mergers and Acquisitions Presentation Deck | 13 slides",
      "authorId": "taboola",
      "authorName": "Taboola",
      "documentKindSlug": "shareholder-letter",
      "documentKindLabel": "Shareholder letter",
      "sourceTypeSlug": "investment_bank",
      "sourceTypeLabel": "Investment bank",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 10,
      "slideType": "propose_solution",
      "function": "present_solution",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-117f-7139-b332-c7921487636f/10",
      "deckHref": "/decks/019de074-117f-7139-b332-c7921487636f",
      "deckAnchorHref": "/decks/019de074-117f-7139-b332-c7921487636f#slide-10",
      "loopMatches": [
        {
          "to": 10,
          "from": 9,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "f37e2460-5beb-410b-90f8-272521031ee4",
          "evidence": "Implied cost of not selecting Taboola",
          "position": 1,
          "objective": "Why Yahoo! selected Taboola",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.5,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 10,
          "from": 9,
          "beatId": "f2a8eea8-9e40-4068-bb01-617ccd48445f",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Solution (Provide relief)",
          "beatSlug": "problem-agitate-solution-solution-provide-relief",
          "evidence": "Why Yahoo! selected Taboola",
          "position": 3,
          "confidence": 0.7,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-117f-7139-b332-c7921487636f",
      "docSlug": "87c4725a75980837aa20227252fd24a0",
      "documentTitle": "Taboola | Mergers and Acquisitions Presentation Deck | 13 slides",
      "authorId": "taboola",
      "authorName": "Taboola",
      "documentKindSlug": "shareholder-letter",
      "documentKindLabel": "Shareholder letter",
      "sourceTypeSlug": "investment_bank",
      "sourceTypeLabel": "Investment bank",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 11,
      "slideType": "appendix",
      "function": "appendix",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-117f-7139-b332-c7921487636f/11",
      "deckHref": "/decks/019de074-117f-7139-b332-c7921487636f",
      "deckAnchorHref": "/decks/019de074-117f-7139-b332-c7921487636f#slide-11",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 13,
          "from": 11,
          "beatId": "c08a6873-9ed0-466b-aec1-4a9c1b07996b",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Resolution",
          "beatSlug": "resolution",
          "evidence": "Appendix and disclosures",
          "position": 4,
          "confidence": 0.7,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-117f-7139-b332-c7921487636f",
      "docSlug": "87c4725a75980837aa20227252fd24a0",
      "documentTitle": "Taboola | Mergers and Acquisitions Presentation Deck | 13 slides",
      "authorId": "taboola",
      "authorName": "Taboola",
      "documentKindSlug": "shareholder-letter",
      "documentKindLabel": "Shareholder letter",
      "sourceTypeSlug": "investment_bank",
      "sourceTypeLabel": "Investment bank",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 12,
      "slideType": "appendix_methodology",
      "function": "other",
      "notes": "The slide serves as a disclosure of the underlying logic for a hypothetical financial scenario.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-117f-7139-b332-c7921487636f/12",
      "deckHref": "/decks/019de074-117f-7139-b332-c7921487636f",
      "deckAnchorHref": "/decks/019de074-117f-7139-b332-c7921487636f#slide-12",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 13,
          "from": 11,
          "beatId": "c08a6873-9ed0-466b-aec1-4a9c1b07996b",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Resolution",
          "beatSlug": "resolution",
          "evidence": "Appendix and disclosures",
          "position": 4,
          "confidence": 0.7,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-117f-7139-b332-c7921487636f",
      "docSlug": "87c4725a75980837aa20227252fd24a0",
      "documentTitle": "Taboola | Mergers and Acquisitions Presentation Deck | 13 slides",
      "authorId": "taboola",
      "authorName": "Taboola",
      "documentKindSlug": "shareholder-letter",
      "documentKindLabel": "Shareholder letter",
      "sourceTypeSlug": "investment_bank",
      "sourceTypeLabel": "Investment bank",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 13,
      "slideType": "appendix_disclosure",
      "function": "other",
      "notes": "Standard financial disclosure slide explaining why GAAP reconciliations for projections are not provided.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-117f-7139-b332-c7921487636f/13",
      "deckHref": "/decks/019de074-117f-7139-b332-c7921487636f",
      "deckAnchorHref": "/decks/019de074-117f-7139-b332-c7921487636f#slide-13",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 13,
          "from": 11,
          "beatId": "c08a6873-9ed0-466b-aec1-4a9c1b07996b",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Resolution",
          "beatSlug": "resolution",
          "evidence": "Appendix and disclosures",
          "position": 4,
          "confidence": 0.7,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-1227-71b8-9517-72a8b70cc8a6",
      "docSlug": "076879a751ec4e35d40f4f317882c468",
      "documentTitle": "Talkspace | Results Presentation Deck | 11 slides",
      "authorId": "talkspace",
      "authorName": "Talkspace",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 1,
      "slideType": "cover",
      "function": "front_matter",
      "notes": "The slide uses a visual collage of product UI to establish brand identity and service scope.",
      "imagePath": "https://imgproxy.kitesheet.com/z-d6yx-PrusWBP0qpsq4BfltY0mgeNc7Q0Lab-mIbQ8/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8wNzY4NzlhNzUxZWM0ZTM1ZDQwZjRmMzE3ODgyYzQ2OC9wMDAxLmpwZw",
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-1227-71b8-9517-72a8b70cc8a6/1",
      "deckHref": "/decks/019de074-1227-71b8-9517-72a8b70cc8a6",
      "deckAnchorHref": "/decks/019de074-1227-71b8-9517-72a8b70cc8a6#slide-1",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": "https://imgproxy.kitesheet.com/pjvhspfJ3lX-iiBMYEbwwrRpCpSHbe3uZOp05AsiEco/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8wNzY4NzlhNzUxZWM0ZTM1ZDQwZjRmMzE3ODgyYzQ2OC9wMDAxLnBuZw",
      "thumbSrc": "https://imgproxy.kitesheet.com/mYpSE-BGh9ki04nkvYoVwcSngDT3OfXre00HK1dgAHo/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8wNzY4NzlhNzUxZWM0ZTM1ZDQwZjRmMzE3ODgyYzQ2OC9wMDAxLmpwZw",
      "thumbSrcAlt": "https://imgproxy.kitesheet.com/DH8s1DSs-Ms4PQXe1_vpJx7c8qXKO3v9Z70dnBdACDg/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8wNzY4NzlhNzUxZWM0ZTM1ZDQwZjRmMzE3ODgyYzQ2OC9wMDAxLnBuZw"
    },
    {
      "docId": "019de074-1227-71b8-9517-72a8b70cc8a6",
      "docSlug": "076879a751ec4e35d40f4f317882c468",
      "documentTitle": "Talkspace | Results Presentation Deck | 11 slides",
      "authorId": "talkspace",
      "authorName": "Talkspace",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 2,
      "slideType": "disclaimer",
      "function": "other",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-1227-71b8-9517-72a8b70cc8a6/2",
      "deckHref": "/decks/019de074-1227-71b8-9517-72a8b70cc8a6",
      "deckAnchorHref": "/decks/019de074-1227-71b8-9517-72a8b70cc8a6#slide-2",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-1227-71b8-9517-72a8b70cc8a6",
      "docSlug": "076879a751ec4e35d40f4f317882c468",
      "documentTitle": "Talkspace | Results Presentation Deck | 11 slides",
      "authorId": "talkspace",
      "authorName": "Talkspace",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 3,
      "slideType": "kpi_overview",
      "function": "analyze_data",
      "notes": "The slide uses three distinct bar charts to compare year-over-year performance.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-1227-71b8-9517-72a8b70cc8a6/3",
      "deckHref": "/decks/019de074-1227-71b8-9517-72a8b70cc8a6",
      "deckAnchorHref": "/decks/019de074-1227-71b8-9517-72a8b70cc8a6#slide-3",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 3,
          "from": 3,
          "beatId": "3591c029-25b4-4cd2-bc95-093973dd6b84",
          "arcName": "Monroe's Motivated Sequence",
          "arcSlug": "monroes-sequence",
          "beatName": "Attention",
          "beatSlug": "monroes-sequence-attention",
          "evidence": "3Q 2022 Performance Highlights",
          "position": 0,
          "confidence": 0.7,
          "parentBeatName": "Hook",
          "parentBeatSlug": "hook"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-1227-71b8-9517-72a8b70cc8a6",
      "docSlug": "076879a751ec4e35d40f4f317882c468",
      "documentTitle": "Talkspace | Results Presentation Deck | 11 slides",
      "authorId": "talkspace",
      "authorName": "Talkspace",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 4,
      "slideType": "key_messages",
      "function": "plan_implementation",
      "notes": "The slide uses a 2x2 grid layout to present four distinct strategic pillars.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-1227-71b8-9517-72a8b70cc8a6/4",
      "deckHref": "/decks/019de074-1227-71b8-9517-72a8b70cc8a6",
      "deckAnchorHref": "/decks/019de074-1227-71b8-9517-72a8b70cc8a6#slide-4",
      "loopMatches": [
        {
          "to": 9,
          "from": 4,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "f4bb2d06-c55d-453a-a9aa-de1d8cd54c8e",
          "evidence": "The deck presents performance metrics to justify the priorities",
          "position": 0,
          "objective": "Highlighting the importance of Talkspace's strategic priorities",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.6,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 4,
          "from": 4,
          "beatId": "4387dc54-7cb5-434f-be2a-8a8a016e480d",
          "arcName": "Monroe's Motivated Sequence",
          "arcSlug": "monroes-sequence",
          "beatName": "Need",
          "beatSlug": "monroes-sequence-need",
          "evidence": "Executing On Our Strategic Priorities",
          "position": 1,
          "confidence": 0.7,
          "parentBeatName": "Complication",
          "parentBeatSlug": "complication"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-1227-71b8-9517-72a8b70cc8a6",
      "docSlug": "076879a751ec4e35d40f4f317882c468",
      "documentTitle": "Talkspace | Results Presentation Deck | 11 slides",
      "authorId": "talkspace",
      "authorName": "Talkspace",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 5,
      "slideType": "kpi_overview",
      "function": "analyze_data",
      "notes": "Revenue chart is a stacked bar chart; Gross Profit chart is a combo chart with bars for profit and dots for margin percentage.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-1227-71b8-9517-72a8b70cc8a6/5",
      "deckHref": "/decks/019de074-1227-71b8-9517-72a8b70cc8a6",
      "deckAnchorHref": "/decks/019de074-1227-71b8-9517-72a8b70cc8a6#slide-5",
      "loopMatches": [
        {
          "to": 9,
          "from": 4,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "f4bb2d06-c55d-453a-a9aa-de1d8cd54c8e",
          "evidence": "The deck presents performance metrics to justify the priorities",
          "position": 0,
          "objective": "Highlighting the importance of Talkspace's strategic priorities",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.6,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 8,
          "from": 5,
          "beatId": "114e1e51-0e00-41cd-9928-6303f732b6b5",
          "arcName": "Monroe's Motivated Sequence",
          "arcSlug": "monroes-sequence",
          "beatName": "Satisfaction",
          "beatSlug": "monroes-sequence-satisfaction",
          "evidence": "Key Performance Metrics and Operating Metrics",
          "position": 2,
          "confidence": 0.7,
          "parentBeatName": "Turn",
          "parentBeatSlug": "turn"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-1227-71b8-9517-72a8b70cc8a6",
      "docSlug": "076879a751ec4e35d40f4f317882c468",
      "documentTitle": "Talkspace | Results Presentation Deck | 11 slides",
      "authorId": "talkspace",
      "authorName": "Talkspace",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 6,
      "slideType": "kpi_overview",
      "function": "analyze_data",
      "notes": "Operating Expenses chart is a stacked bar chart showing OpEx vs SBC + Non-Recurring expenses.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-1227-71b8-9517-72a8b70cc8a6/6",
      "deckHref": "/decks/019de074-1227-71b8-9517-72a8b70cc8a6",
      "deckAnchorHref": "/decks/019de074-1227-71b8-9517-72a8b70cc8a6#slide-6",
      "loopMatches": [
        {
          "to": 9,
          "from": 4,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "f4bb2d06-c55d-453a-a9aa-de1d8cd54c8e",
          "evidence": "The deck presents performance metrics to justify the priorities",
          "position": 0,
          "objective": "Highlighting the importance of Talkspace's strategic priorities",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.6,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 8,
          "from": 5,
          "beatId": "114e1e51-0e00-41cd-9928-6303f732b6b5",
          "arcName": "Monroe's Motivated Sequence",
          "arcSlug": "monroes-sequence",
          "beatName": "Satisfaction",
          "beatSlug": "monroes-sequence-satisfaction",
          "evidence": "Key Performance Metrics and Operating Metrics",
          "position": 2,
          "confidence": 0.7,
          "parentBeatName": "Turn",
          "parentBeatSlug": "turn"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-1227-71b8-9517-72a8b70cc8a6",
      "docSlug": "076879a751ec4e35d40f4f317882c468",
      "documentTitle": "Talkspace | Results Presentation Deck | 11 slides",
      "authorId": "talkspace",
      "authorName": "Talkspace",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 7,
      "slideType": "kpi_overview",
      "function": "summarize",
      "notes": "DTE stands for Direct-to-Enterprise; MBH & EAP stands for Mental Health Benefit & Employee Assistance Program.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-1227-71b8-9517-72a8b70cc8a6/7",
      "deckHref": "/decks/019de074-1227-71b8-9517-72a8b70cc8a6",
      "deckAnchorHref": "/decks/019de074-1227-71b8-9517-72a8b70cc8a6#slide-7",
      "loopMatches": [
        {
          "to": 9,
          "from": 4,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "f4bb2d06-c55d-453a-a9aa-de1d8cd54c8e",
          "evidence": "The deck presents performance metrics to justify the priorities",
          "position": 0,
          "objective": "Highlighting the importance of Talkspace's strategic priorities",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.6,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 8,
          "from": 5,
          "beatId": "114e1e51-0e00-41cd-9928-6303f732b6b5",
          "arcName": "Monroe's Motivated Sequence",
          "arcSlug": "monroes-sequence",
          "beatName": "Satisfaction",
          "beatSlug": "monroes-sequence-satisfaction",
          "evidence": "Key Performance Metrics and Operating Metrics",
          "position": 2,
          "confidence": 0.7,
          "parentBeatName": "Turn",
          "parentBeatSlug": "turn"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-1227-71b8-9517-72a8b70cc8a6",
      "docSlug": "076879a751ec4e35d40f4f317882c468",
      "documentTitle": "Talkspace | Results Presentation Deck | 11 slides",
      "authorId": "talkspace",
      "authorName": "Talkspace",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 8,
      "slideType": "kpi_overview",
      "function": "analyze_data",
      "notes": "The advertising spend chart shows percentage decreases quarter-over-quarter.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-1227-71b8-9517-72a8b70cc8a6/8",
      "deckHref": "/decks/019de074-1227-71b8-9517-72a8b70cc8a6",
      "deckAnchorHref": "/decks/019de074-1227-71b8-9517-72a8b70cc8a6#slide-8",
      "loopMatches": [
        {
          "to": 9,
          "from": 4,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "f4bb2d06-c55d-453a-a9aa-de1d8cd54c8e",
          "evidence": "The deck presents performance metrics to justify the priorities",
          "position": 0,
          "objective": "Highlighting the importance of Talkspace's strategic priorities",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.6,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 8,
          "from": 5,
          "beatId": "114e1e51-0e00-41cd-9928-6303f732b6b5",
          "arcName": "Monroe's Motivated Sequence",
          "arcSlug": "monroes-sequence",
          "beatName": "Satisfaction",
          "beatSlug": "monroes-sequence-satisfaction",
          "evidence": "Key Performance Metrics and Operating Metrics",
          "position": 2,
          "confidence": 0.7,
          "parentBeatName": "Turn",
          "parentBeatSlug": "turn"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-1227-71b8-9517-72a8b70cc8a6",
      "docSlug": "076879a751ec4e35d40f4f317882c468",
      "documentTitle": "Talkspace | Results Presentation Deck | 11 slides",
      "authorId": "talkspace",
      "authorName": "Talkspace",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 9,
      "slideType": "key_takeaways",
      "function": "summarize",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-1227-71b8-9517-72a8b70cc8a6/9",
      "deckHref": "/decks/019de074-1227-71b8-9517-72a8b70cc8a6",
      "deckAnchorHref": "/decks/019de074-1227-71b8-9517-72a8b70cc8a6#slide-9",
      "loopMatches": [
        {
          "to": 9,
          "from": 4,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "f4bb2d06-c55d-453a-a9aa-de1d8cd54c8e",
          "evidence": "The deck presents performance metrics to justify the priorities",
          "position": 0,
          "objective": "Highlighting the importance of Talkspace's strategic priorities",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.6,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 9,
          "from": 9,
          "beatId": "35d01b56-17f1-4e4e-975e-a4231bfcc35d",
          "arcName": "Monroe's Motivated Sequence",
          "arcSlug": "monroes-sequence",
          "beatName": "Action",
          "beatSlug": "monroes-sequence-action",
          "evidence": "Closing Remarks",
          "position": 3,
          "confidence": 0.7,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-1227-71b8-9517-72a8b70cc8a6",
      "docSlug": "076879a751ec4e35d40f4f317882c468",
      "documentTitle": "Talkspace | Results Presentation Deck | 11 slides",
      "authorId": "talkspace",
      "authorName": "Talkspace",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 10,
      "slideType": "appendix",
      "function": "appendix",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-1227-71b8-9517-72a8b70cc8a6/10",
      "deckHref": "/decks/019de074-1227-71b8-9517-72a8b70cc8a6",
      "deckAnchorHref": "/decks/019de074-1227-71b8-9517-72a8b70cc8a6#slide-10",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-1227-71b8-9517-72a8b70cc8a6",
      "docSlug": "076879a751ec4e35d40f4f317882c468",
      "documentTitle": "Talkspace | Results Presentation Deck | 11 slides",
      "authorId": "talkspace",
      "authorName": "Talkspace",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 11,
      "slideType": "appendix_data",
      "function": "analyze_data",
      "notes": "Includes footnotes explaining financial income and non-recurring expenses.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-1227-71b8-9517-72a8b70cc8a6/11",
      "deckHref": "/decks/019de074-1227-71b8-9517-72a8b70cc8a6",
      "deckAnchorHref": "/decks/019de074-1227-71b8-9517-72a8b70cc8a6#slide-11",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-1317-767b-825b-77b5f795fc6c",
      "docSlug": "27adacda91e6c92061c4de59bd9e9dc9",
      "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 44 slides",
      "authorId": "theravance-biopharma",
      "authorName": "Theravance Biopharma",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 1,
      "slideType": "cover",
      "function": "front_matter",
      "notes": null,
      "imagePath": "https://imgproxy.kitesheet.com/08XZcz8IKqTAAQ9FiW6J1llYOyAwkMHpaCE8croqKkc/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8yN2FkYWNkYTkxZTZjOTIwNjFjNGRlNTliZDllOWRjOS9wMDAxLmpwZw",
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-1317-767b-825b-77b5f795fc6c/1",
      "deckHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c",
      "deckAnchorHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c#slide-1",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": "https://imgproxy.kitesheet.com/PpxzUyHF3MV6J6nNZh2C2jmusgZ5fziuP9NF4BOlttA/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8yN2FkYWNkYTkxZTZjOTIwNjFjNGRlNTliZDllOWRjOS9wMDAxLnBuZw",
      "thumbSrc": "https://imgproxy.kitesheet.com/jKa0NIb-hDdhvv6MCwwBzb4GLzpuTE0RgPU6FYfZkEI/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8yN2FkYWNkYTkxZTZjOTIwNjFjNGRlNTliZDllOWRjOS9wMDAxLmpwZw",
      "thumbSrcAlt": "https://imgproxy.kitesheet.com/eSrvQ_t9n-L6TCaniZK-34i-L7QthWMCQtZFv9EynHA/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8yN2FkYWNkYTkxZTZjOTIwNjFjNGRlNTliZDllOWRjOS9wMDAxLnBuZw"
    },
    {
      "docId": "019de074-1317-767b-825b-77b5f795fc6c",
      "docSlug": "27adacda91e6c92061c4de59bd9e9dc9",
      "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 44 slides",
      "authorId": "theravance-biopharma",
      "authorName": "Theravance Biopharma",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 2,
      "slideType": "cover",
      "function": "front_matter",
      "notes": "Poster #117",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-1317-767b-825b-77b5f795fc6c/2",
      "deckHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c",
      "deckAnchorHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c#slide-2",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-1317-767b-825b-77b5f795fc6c",
      "docSlug": "27adacda91e6c92061c4de59bd9e9dc9",
      "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 44 slides",
      "authorId": "theravance-biopharma",
      "authorName": "Theravance Biopharma",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 3,
      "slideType": "appendix_disclosure",
      "function": "other",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-1317-767b-825b-77b5f795fc6c/3",
      "deckHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c",
      "deckAnchorHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c#slide-3",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-1317-767b-825b-77b5f795fc6c",
      "docSlug": "27adacda91e6c92061c4de59bd9e9dc9",
      "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 44 slides",
      "authorId": "theravance-biopharma",
      "authorName": "Theravance Biopharma",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 4,
      "slideType": "agenda",
      "function": "transition",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-1317-767b-825b-77b5f795fc6c/4",
      "deckHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c",
      "deckAnchorHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c#slide-4",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-1317-767b-825b-77b5f795fc6c",
      "docSlug": "27adacda91e6c92061c4de59bd9e9dc9",
      "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 44 slides",
      "authorId": "theravance-biopharma",
      "authorName": "Theravance Biopharma",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 5,
      "slideType": "problem_statement",
      "function": "frame_problem",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-1317-767b-825b-77b5f795fc6c/5",
      "deckHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c",
      "deckAnchorHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c#slide-5",
      "loopMatches": [
        {
          "to": 9,
          "from": 5,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "c2344040-10ec-4946-8746-a14cdce330db",
          "evidence": "The deck highlights the limitations of current treatments and the worsening of symptoms in patients with nOH.",
          "position": 2,
          "objective": "What are the consequences of not treating nOH effectively?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.6,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 5,
          "from": 5,
          "beatId": "fab8ea22-2a42-43d7-b7f9-c4735dc0454e",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Problem (Identify pain)",
          "beatSlug": "problem-agitate-solution-problem-identify-pain",
          "evidence": "The deck identifies nOH as a condition with limited treatment options and significant symptoms.",
          "position": 0,
          "confidence": 0.8,
          "parentBeatName": "Complication",
          "parentBeatSlug": "complication"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-1317-767b-825b-77b5f795fc6c",
      "docSlug": "27adacda91e6c92061c4de59bd9e9dc9",
      "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 44 slides",
      "authorId": "theravance-biopharma",
      "authorName": "Theravance Biopharma",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 6,
      "slideType": "comparison_table",
      "function": "compare_peers",
      "notes": "The slide uses anatomical diagrams to illustrate the spread of alpha-synuclein (labeled 'α') across the nervous system for three different neurodegenerative conditions.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-1317-767b-825b-77b5f795fc6c/6",
      "deckHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c",
      "deckAnchorHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c#slide-6",
      "loopMatches": [
        {
          "to": 9,
          "from": 5,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "c2344040-10ec-4946-8746-a14cdce330db",
          "evidence": "The deck highlights the limitations of current treatments and the worsening of symptoms in patients with nOH.",
          "position": 2,
          "objective": "What are the consequences of not treating nOH effectively?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.6,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 9,
          "from": 6,
          "beatId": "29ae0a7e-aeb5-49e1-91d1-0a829a543cc3",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Agitate (Make it worse)",
          "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
          "evidence": "The deck highlights the limitations of current treatments and the worsening of symptoms in patients with nOH.",
          "position": 1,
          "confidence": 0.8,
          "parentBeatName": "Development",
          "parentBeatSlug": "development"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-1317-767b-825b-77b5f795fc6c",
      "docSlug": "27adacda91e6c92061c4de59bd9e9dc9",
      "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 44 slides",
      "authorId": "theravance-biopharma",
      "authorName": "Theravance Biopharma",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 7,
      "slideType": "other",
      "function": "present_framework",
      "notes": "The slide uses a biological process diagram to explain the mechanism of action for midodrine and droxidopa in the context of autonomic disorders.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-1317-767b-825b-77b5f795fc6c/7",
      "deckHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c",
      "deckAnchorHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c#slide-7",
      "loopMatches": [
        {
          "to": 9,
          "from": 5,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "c2344040-10ec-4946-8746-a14cdce330db",
          "evidence": "The deck highlights the limitations of current treatments and the worsening of symptoms in patients with nOH.",
          "position": 2,
          "objective": "What are the consequences of not treating nOH effectively?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.6,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 9,
          "from": 6,
          "beatId": "29ae0a7e-aeb5-49e1-91d1-0a829a543cc3",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Agitate (Make it worse)",
          "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
          "evidence": "The deck highlights the limitations of current treatments and the worsening of symptoms in patients with nOH.",
          "position": 1,
          "confidence": 0.8,
          "parentBeatName": "Development",
          "parentBeatSlug": "development"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-1317-767b-825b-77b5f795fc6c",
      "docSlug": "27adacda91e6c92061c4de59bd9e9dc9",
      "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 44 slides",
      "authorId": "theravance-biopharma",
      "authorName": "Theravance Biopharma",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 8,
      "slideType": "problem_statement",
      "function": "diagnose_problem",
      "notes": "Includes a screenshot of a BMC Neurology paper and a bar chart showing subgroup analysis of OHSA scores.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-1317-767b-825b-77b5f795fc6c/8",
      "deckHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c",
      "deckAnchorHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c#slide-8",
      "loopMatches": [
        {
          "to": 9,
          "from": 5,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "c2344040-10ec-4946-8746-a14cdce330db",
          "evidence": "The deck highlights the limitations of current treatments and the worsening of symptoms in patients with nOH.",
          "position": 2,
          "objective": "What are the consequences of not treating nOH effectively?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.6,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 9,
          "from": 6,
          "beatId": "29ae0a7e-aeb5-49e1-91d1-0a829a543cc3",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Agitate (Make it worse)",
          "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
          "evidence": "The deck highlights the limitations of current treatments and the worsening of symptoms in patients with nOH.",
          "position": 1,
          "confidence": 0.8,
          "parentBeatName": "Development",
          "parentBeatSlug": "development"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-1317-767b-825b-77b5f795fc6c",
      "docSlug": "27adacda91e6c92061c4de59bd9e9dc9",
      "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 44 slides",
      "authorId": "theravance-biopharma",
      "authorName": "Theravance Biopharma",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 9,
      "slideType": "other",
      "function": "present_framework",
      "notes": "The slide uses a biological process diagram to explain how different drugs (agonists, precursors, reuptake inhibitors) affect sympathetic signaling to blood vessels.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-1317-767b-825b-77b5f795fc6c/9",
      "deckHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c",
      "deckAnchorHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c#slide-9",
      "loopMatches": [
        {
          "to": 9,
          "from": 5,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "c2344040-10ec-4946-8746-a14cdce330db",
          "evidence": "The deck highlights the limitations of current treatments and the worsening of symptoms in patients with nOH.",
          "position": 2,
          "objective": "What are the consequences of not treating nOH effectively?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.6,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 9,
          "from": 6,
          "beatId": "29ae0a7e-aeb5-49e1-91d1-0a829a543cc3",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Agitate (Make it worse)",
          "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
          "evidence": "The deck highlights the limitations of current treatments and the worsening of symptoms in patients with nOH.",
          "position": 1,
          "confidence": 0.8,
          "parentBeatName": "Development",
          "parentBeatSlug": "development"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-1317-767b-825b-77b5f795fc6c",
      "docSlug": "27adacda91e6c92061c4de59bd9e9dc9",
      "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 44 slides",
      "authorId": "theravance-biopharma",
      "authorName": "Theravance Biopharma",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 10,
      "slideType": "propose_solution",
      "function": "present_solution",
      "notes": "The slide uses a biological process diagram to explain the drug's mechanism of action.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-1317-767b-825b-77b5f795fc6c/10",
      "deckHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c",
      "deckAnchorHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c#slide-10",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 16,
          "from": 10,
          "beatId": "2bf24754-8a89-445c-8223-ba21794de27d",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Solution (Provide relief)",
          "beatSlug": "problem-agitate-solution-solution-provide-relief",
          "evidence": "The deck presents ampreloxetine as a novel pharmacological strategy for treating nOH, with data on its efficacy and safety.",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-1317-767b-825b-77b5f795fc6c",
      "docSlug": "27adacda91e6c92061c4de59bd9e9dc9",
      "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 44 slides",
      "authorId": "theravance-biopharma",
      "authorName": "Theravance Biopharma",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 11,
      "slideType": "appendix_methodology",
      "function": "present_framework",
      "notes": "The slide uses a process flow diagram to show how patients transition from Study 0169 to 0170.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-1317-767b-825b-77b5f795fc6c/11",
      "deckHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c",
      "deckAnchorHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c#slide-11",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 16,
          "from": 10,
          "beatId": "2bf24754-8a89-445c-8223-ba21794de27d",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Solution (Provide relief)",
          "beatSlug": "problem-agitate-solution-solution-provide-relief",
          "evidence": "The deck presents ampreloxetine as a novel pharmacological strategy for treating nOH, with data on its efficacy and safety.",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-1317-767b-825b-77b5f795fc6c",
      "docSlug": "27adacda91e6c92061c4de59bd9e9dc9",
      "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 44 slides",
      "authorId": "theravance-biopharma",
      "authorName": "Theravance Biopharma",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 12,
      "slideType": "key_takeaways",
      "function": "analyze_data",
      "notes": "The slide shows a significant increase in Norepinephrine levels with Ampreloxetine treatment compared to placebo.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-1317-767b-825b-77b5f795fc6c/12",
      "deckHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c",
      "deckAnchorHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c#slide-12",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 16,
          "from": 10,
          "beatId": "2bf24754-8a89-445c-8223-ba21794de27d",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Solution (Provide relief)",
          "beatSlug": "problem-agitate-solution-solution-provide-relief",
          "evidence": "The deck presents ampreloxetine as a novel pharmacological strategy for treating nOH, with data on its efficacy and safety.",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        },
        {
          "to": 13,
          "from": 12,
          "beatId": "7a988e2a-a157-4ca0-ae80-d16ea9c4bca8",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Key Takeaways",
          "beatSlug": null,
          "evidence": "The deck summarizes key takeaways on ampreloxetine's benefits in MSA patients.",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-1317-767b-825b-77b5f795fc6c",
      "docSlug": "27adacda91e6c92061c4de59bd9e9dc9",
      "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 44 slides",
      "authorId": "theravance-biopharma",
      "authorName": "Theravance Biopharma",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 13,
      "slideType": "before_after",
      "function": "analyze_data",
      "notes": "Study 0169 data showing significant increases in Norepinephrine and decreases in DHPG across three patient cohorts.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-1317-767b-825b-77b5f795fc6c/13",
      "deckHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c",
      "deckAnchorHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c#slide-13",
      "loopMatches": [
        {
          "to": 13,
          "from": 13,
          "name": "Aha Moment",
          "slug": "03-aha-moment",
          "bestFor": "Data-heavy sections, research findings, analytical arguments",
          "matchId": "1d1e1156-9f19-4a7c-a60c-f5d290947ba3",
          "evidence": "The deck presents data on the greatest improvements in plasma NE levels in patients with MSA.",
          "position": 0,
          "objective": "What are the key benefits of ampreloxetine in MSA patients?",
          "structure": "The Problem/Question -> What the Data Shows -> The Insight",
          "confidence": 0.7,
          "description": "Establish a tension, present data, then deliver the insight that changes everything"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 16,
          "from": 10,
          "beatId": "2bf24754-8a89-445c-8223-ba21794de27d",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Solution (Provide relief)",
          "beatSlug": "problem-agitate-solution-solution-provide-relief",
          "evidence": "The deck presents ampreloxetine as a novel pharmacological strategy for treating nOH, with data on its efficacy and safety.",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        },
        {
          "to": 13,
          "from": 12,
          "beatId": "7a988e2a-a157-4ca0-ae80-d16ea9c4bca8",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Key Takeaways",
          "beatSlug": null,
          "evidence": "The deck summarizes key takeaways on ampreloxetine's benefits in MSA patients.",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-1317-767b-825b-77b5f795fc6c",
      "docSlug": "27adacda91e6c92061c4de59bd9e9dc9",
      "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 44 slides",
      "authorId": "theravance-biopharma",
      "authorName": "Theravance Biopharma",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 14,
      "slideType": "before_after",
      "function": "analyze_data",
      "notes": "The chart illustrates a worsening of blood pressure in the placebo group compared to the treatment group.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-1317-767b-825b-77b5f795fc6c/14",
      "deckHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c",
      "deckAnchorHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c#slide-14",
      "loopMatches": [
        {
          "to": 15,
          "from": 14,
          "name": "Before After",
          "slug": "21-before-after",
          "bestFor": "Product demos, process improvements, ROI justification",
          "matchId": "a4dcdb2a-fc55-413c-9925-eca26ad6fa16",
          "evidence": "The deck presents data on the effect of ampreloxetine treatment on 3-minute standing SBP in MSA patients.",
          "position": 1,
          "objective": "How does ampreloxetine treatment affect 3-minute standing SBP in MSA patients?",
          "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta",
          "confidence": 0.7,
          "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 16,
          "from": 10,
          "beatId": "2bf24754-8a89-445c-8223-ba21794de27d",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Solution (Provide relief)",
          "beatSlug": "problem-agitate-solution-solution-provide-relief",
          "evidence": "The deck presents ampreloxetine as a novel pharmacological strategy for treating nOH, with data on its efficacy and safety.",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-1317-767b-825b-77b5f795fc6c",
      "docSlug": "27adacda91e6c92061c4de59bd9e9dc9",
      "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 44 slides",
      "authorId": "theravance-biopharma",
      "authorName": "Theravance Biopharma",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 15,
      "slideType": "before_after",
      "function": "analyze_data",
      "notes": "The slide uses a bar chart with error bars to show treatment effects. 'Worsening' is indicated by a downward arrow on the right.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-1317-767b-825b-77b5f795fc6c/15",
      "deckHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c",
      "deckAnchorHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c#slide-15",
      "loopMatches": [
        {
          "to": 15,
          "from": 14,
          "name": "Before After",
          "slug": "21-before-after",
          "bestFor": "Product demos, process improvements, ROI justification",
          "matchId": "a4dcdb2a-fc55-413c-9925-eca26ad6fa16",
          "evidence": "The deck presents data on the effect of ampreloxetine treatment on 3-minute standing SBP in MSA patients.",
          "position": 1,
          "objective": "How does ampreloxetine treatment affect 3-minute standing SBP in MSA patients?",
          "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta",
          "confidence": 0.7,
          "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 16,
          "from": 10,
          "beatId": "2bf24754-8a89-445c-8223-ba21794de27d",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Solution (Provide relief)",
          "beatSlug": "problem-agitate-solution-solution-provide-relief",
          "evidence": "The deck presents ampreloxetine as a novel pharmacological strategy for treating nOH, with data on its efficacy and safety.",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-1317-767b-825b-77b5f795fc6c",
      "docSlug": "27adacda91e6c92061c4de59bd9e9dc9",
      "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 44 slides",
      "authorId": "theravance-biopharma",
      "authorName": "Theravance Biopharma",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 16,
      "slideType": "key_takeaways",
      "function": "summarize",
      "notes": "Includes a footer with abbreviations for BP, DHPG, MSA, NE, and nOH.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-1317-767b-825b-77b5f795fc6c/16",
      "deckHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c",
      "deckAnchorHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c#slide-16",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 16,
          "from": 10,
          "beatId": "2bf24754-8a89-445c-8223-ba21794de27d",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Solution (Provide relief)",
          "beatSlug": "problem-agitate-solution-solution-provide-relief",
          "evidence": "The deck presents ampreloxetine as a novel pharmacological strategy for treating nOH, with data on its efficacy and safety.",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        },
        {
          "to": 16,
          "from": 16,
          "beatId": "a882952c-c7f7-42b4-8f29-e01dd36eaf43",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Conclusion",
          "beatSlug": null,
          "evidence": "The deck concludes with a summary of ampreloxetine's potential as a treatment option for nOH.",
          "position": 5,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-1317-767b-825b-77b5f795fc6c",
      "docSlug": "27adacda91e6c92061c4de59bd9e9dc9",
      "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 44 slides",
      "authorId": "theravance-biopharma",
      "authorName": "Theravance Biopharma",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 17,
      "slideType": "cover",
      "function": "front_matter",
      "notes": "Poster #106",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-1317-767b-825b-77b5f795fc6c/17",
      "deckHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c",
      "deckAnchorHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c#slide-17",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-1317-767b-825b-77b5f795fc6c",
      "docSlug": "27adacda91e6c92061c4de59bd9e9dc9",
      "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 44 slides",
      "authorId": "theravance-biopharma",
      "authorName": "Theravance Biopharma",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 18,
      "slideType": "appendix_disclosure",
      "function": "other",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-1317-767b-825b-77b5f795fc6c/18",
      "deckHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c",
      "deckAnchorHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c#slide-18",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-1317-767b-825b-77b5f795fc6c",
      "docSlug": "27adacda91e6c92061c4de59bd9e9dc9",
      "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 44 slides",
      "authorId": "theravance-biopharma",
      "authorName": "Theravance Biopharma",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 19,
      "slideType": "appendix_methodology",
      "function": "illustrate_case",
      "notes": "The slide highlights the failure of Study 0169 and the subsequent early termination of Study 0170.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-1317-767b-825b-77b5f795fc6c/19",
      "deckHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c",
      "deckAnchorHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c#slide-19",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-1317-767b-825b-77b5f795fc6c",
      "docSlug": "27adacda91e6c92061c4de59bd9e9dc9",
      "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 44 slides",
      "authorId": "theravance-biopharma",
      "authorName": "Theravance Biopharma",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 20,
      "slideType": "appendix_methodology",
      "function": "present_framework",
      "notes": "The slide outlines a complex clinical trial structure involving rollovers from Study 0169 and de novo participants, leading into a randomized withdrawal period.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-1317-767b-825b-77b5f795fc6c/20",
      "deckHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c",
      "deckAnchorHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c#slide-20",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-1317-767b-825b-77b5f795fc6c",
      "docSlug": "27adacda91e6c92061c4de59bd9e9dc9",
      "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 44 slides",
      "authorId": "theravance-biopharma",
      "authorName": "Theravance Biopharma",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 21,
      "slideType": "appendix_methodology",
      "function": "present_framework",
      "notes": "The slide uses a flow diagram to illustrate study design and participant disposition.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-1317-767b-825b-77b5f795fc6c/21",
      "deckHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c",
      "deckAnchorHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c#slide-21",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-1317-767b-825b-77b5f795fc6c",
      "docSlug": "27adacda91e6c92061c4de59bd9e9dc9",
      "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 44 slides",
      "authorId": "theravance-biopharma",
      "authorName": "Theravance Biopharma",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 22,
      "slideType": "appendix_data",
      "function": "analyze_data",
      "notes": "The slide provides a standard 'Table 1' style clinical trial baseline characteristic summary.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-1317-767b-825b-77b5f795fc6c/22",
      "deckHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c",
      "deckAnchorHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c#slide-22",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-1317-767b-825b-77b5f795fc6c",
      "docSlug": "27adacda91e6c92061c4de59bd9e9dc9",
      "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 44 slides",
      "authorId": "theravance-biopharma",
      "authorName": "Theravance Biopharma",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 23,
      "slideType": "appendix_data",
      "function": "analyze_data",
      "notes": "The slide shows patient counts and percentages for study completion and various reasons for discontinuation.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-1317-767b-825b-77b5f795fc6c/23",
      "deckHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c",
      "deckAnchorHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c#slide-23",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-1317-767b-825b-77b5f795fc6c",
      "docSlug": "27adacda91e6c92061c4de59bd9e9dc9",
      "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 44 slides",
      "authorId": "theravance-biopharma",
      "authorName": "Theravance Biopharma",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 24,
      "slideType": "other",
      "function": "analyze_data",
      "notes": "The slide uses a forest plot to visualize the odds ratio (0.60) with a 95% confidence interval (0.27, 1.29) crossing the null value of 1.0.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-1317-767b-825b-77b5f795fc6c/24",
      "deckHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c",
      "deckAnchorHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c#slide-24",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-1317-767b-825b-77b5f795fc6c",
      "docSlug": "27adacda91e6c92061c4de59bd9e9dc9",
      "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 44 slides",
      "authorId": "theravance-biopharma",
      "authorName": "Theravance Biopharma",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 25,
      "slideType": "appendix_methodology",
      "function": "diagnose_problem",
      "notes": "Uses a visual comparison to explain the biological mechanism of action.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-1317-767b-825b-77b5f795fc6c/25",
      "deckHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c",
      "deckAnchorHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c#slide-25",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-1317-767b-825b-77b5f795fc6c",
      "docSlug": "27adacda91e6c92061c4de59bd9e9dc9",
      "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 44 slides",
      "authorId": "theravance-biopharma",
      "authorName": "Theravance Biopharma",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 26,
      "slideType": "kpi_overview",
      "function": "analyze_data",
      "notes": "The slide highlights the MSA subgroup with a blue box, suggesting a focus on this specific finding.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-1317-767b-825b-77b5f795fc6c/26",
      "deckHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c",
      "deckAnchorHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c#slide-26",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 27,
          "from": 26,
          "beatId": "c3986982-ab55-4193-8105-cf687f288702",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "KPI Overview",
          "beatSlug": null,
          "evidence": "The deck presents data on the trend for benefit in the MSA subpopulation based on prespecified subgroup analyses.",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-1317-767b-825b-77b5f795fc6c",
      "docSlug": "27adacda91e6c92061c4de59bd9e9dc9",
      "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 44 slides",
      "authorId": "theravance-biopharma",
      "authorName": "Theravance Biopharma",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 27,
      "slideType": "key_takeaways",
      "function": "analyze_data",
      "notes": "The slide uses forest plots to compare treatment effects (ampreloxetine vs placebo) across different patient populations (Overall, MSA, PD, PAF).",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-1317-767b-825b-77b5f795fc6c/27",
      "deckHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c",
      "deckAnchorHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c#slide-27",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 27,
          "from": 26,
          "beatId": "c3986982-ab55-4193-8105-cf687f288702",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "KPI Overview",
          "beatSlug": null,
          "evidence": "The deck presents data on the trend for benefit in the MSA subpopulation based on prespecified subgroup analyses.",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-1317-767b-825b-77b5f795fc6c",
      "docSlug": "27adacda91e6c92061c4de59bd9e9dc9",
      "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 44 slides",
      "authorId": "theravance-biopharma",
      "authorName": "Theravance Biopharma",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 28,
      "slideType": "kpi_overview",
      "function": "analyze_data",
      "notes": "The slide includes a table of adverse events and bulleted takeaways regarding clinical safety parameters.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-1317-767b-825b-77b5f795fc6c/28",
      "deckHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c",
      "deckAnchorHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c#slide-28",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-1317-767b-825b-77b5f795fc6c",
      "docSlug": "27adacda91e6c92061c4de59bd9e9dc9",
      "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 44 slides",
      "authorId": "theravance-biopharma",
      "authorName": "Theravance Biopharma",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 29,
      "slideType": "key_takeaways",
      "function": "summarize",
      "notes": "The slide includes a list of authors for a related longitudinal analysis.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-1317-767b-825b-77b5f795fc6c/29",
      "deckHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c",
      "deckAnchorHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c#slide-29",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-1317-767b-825b-77b5f795fc6c",
      "docSlug": "27adacda91e6c92061c4de59bd9e9dc9",
      "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 44 slides",
      "authorId": "theravance-biopharma",
      "authorName": "Theravance Biopharma",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 30,
      "slideType": "cover",
      "function": "front_matter",
      "notes": "Poster #4",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-1317-767b-825b-77b5f795fc6c/30",
      "deckHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c",
      "deckAnchorHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c#slide-30",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-1317-767b-825b-77b5f795fc6c",
      "docSlug": "27adacda91e6c92061c4de59bd9e9dc9",
      "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 44 slides",
      "authorId": "theravance-biopharma",
      "authorName": "Theravance Biopharma",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 31,
      "slideType": "appendix_disclosure",
      "function": "front_matter",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-1317-767b-825b-77b5f795fc6c/31",
      "deckHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c",
      "deckAnchorHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c#slide-31",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-1317-767b-825b-77b5f795fc6c",
      "docSlug": "27adacda91e6c92061c4de59bd9e9dc9",
      "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 44 slides",
      "authorId": "theravance-biopharma",
      "authorName": "Theravance Biopharma",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 32,
      "slideType": "key_takeaways",
      "function": "summarize",
      "notes": "The slide uses a bulleted list to frame the clinical trial narrative from failure to a focused subgroup opportunity.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-1317-767b-825b-77b5f795fc6c/32",
      "deckHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c",
      "deckAnchorHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c#slide-32",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-1317-767b-825b-77b5f795fc6c",
      "docSlug": "27adacda91e6c92061c4de59bd9e9dc9",
      "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 44 slides",
      "authorId": "theravance-biopharma",
      "authorName": "Theravance Biopharma",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 33,
      "slideType": "problem_statement",
      "function": "diagnose_problem",
      "notes": "The slide uses a biological mechanism diagram to illustrate the drug's effect on norepinephrine reuptake.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-1317-767b-825b-77b5f795fc6c/33",
      "deckHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c",
      "deckAnchorHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c#slide-33",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-1317-767b-825b-77b5f795fc6c",
      "docSlug": "27adacda91e6c92061c4de59bd9e9dc9",
      "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 44 slides",
      "authorId": "theravance-biopharma",
      "authorName": "Theravance Biopharma",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 34,
      "slideType": "appendix_methodology",
      "function": "present_framework",
      "notes": "The slide outlines a clinical trial program involving three studies (0169, 0170, 0171) with specific eligibility criteria and endpoints for a longitudinal analysis.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de074-1317-767b-825b-77b5f795fc6c/34",
      "deckHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c",
      "deckAnchorHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c#slide-34",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    }
  ]
}